Relationship Between Levels of Advanced Glycation End Products and Their Soluble Receptor and Adverse Outcomes in Adults With Type 2 Diabetes
Merlin C Thomas, Mark Woodward, Bruce Neal, Qiang Li, Raelene Pickering, Michel Marre, Bryan Williams, Vlado Perkovic, Mark E Cooper, Sophia Zoungas, John Chalmers, Graham S Hillis
DIABETES CARE | AMER DIABETES ASSOC | Published : 2015
OBJECTIVE: This study explored whether activation of the receptor for advanced glycation end products (RAGE) is implicated in the development of diabetes complications. RESEARCH DESIGN AND METHODS: A case-cohort study was performed in 3,763 participants with prevalent diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. The hazard ratios (HRs) for death, major cardiovascular events, and new or worsening nephropathy were derived using Cox regression models, and the ability of sRAGE and AGE levels to reclassify the risk of nephropathy was assessed. RESULTS: After adjustment for a range of possible confounders an..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by National Institute for Health Research
This work was supported by a National Health and Medical Research Council (NHMRC) of Australia project grant (632507). The Diabetes Australia Research Trust helped to fund the hs-cTnT, NT-proBNP, and hs-CRP assays. M.W. has a Principal Research Fellowship and B.N. a Senior Research Fellowship from the NHMRC. M.W., B.N., V.P., and J.C. hold an NHMRC Program Grant.